Atari, M. I., Chappell, M. J., Errington, Rachel J., Smith, Paul J. and Evans, N. D. (2010) A coupled kinetic-dynamic model characterising cell cycle response to an anti-cancer agent. In: 8th Central European Symposium on Pharmaceutical Technology , Graz, Austria, Sep 16 - 18, 2010. Published in: Scientia Pharmaceutica , Vol.78 (No.3). p. 718.

Full text not available from this repository.

Abstract

Topotecan (TPT) is a semi-synthetic derivative of the natural extract camptothecin, which has been found to act as an inhibitor of the DNA enzyme topoisomerase I in a specific and reversible fashion. The drug undergoes
reversible hydrolysis from the pharmacologically active parent lactone form (TPTL) to an inactive hydroxy acid form. In the cytoplasm the irreversible inactivation of TPTL is catalysed by the enzyme aldehyde dehydrogenase
(ALDH). Over-expression of the human breast cancern resistance protein (BCRP/ABCG2) has been linked to high levels of resistance to the anti-cancer agent TPT by promoting an active efflux pump mechanism. The expressions of both ALDH and BCRP have been experimentally identified in a large number of solid tumours and thus play an important role in clinical drug resistance of cancers. To investigate the catalytic reaction and efflux pump mechanism, a compartmental model for the in vitro uptake kinetics of TPT has been extended to better describe the drug activity and delivery of TPTL to the DNA target as
well as the catalysis by ALDH and the elimination of drug from the cytoplasm via the efflux pump. All unknown model parameters were uniquely estimated to a high level of confidence. Model simulations have been compared with live
human breast cancer cells (MCF-7 cell line) data and found to give good qualitative agreement. The kinetic model has then been linked to a cell cycle model, based on [1], which facilitates analysis of the response of the growth of single cells in the presence and absence of TPT. Parameter estimation is performed using green fluorescent protein tagged cyclin B1 (cell cycle regulatory protein) data for the osteosarcoma cell line U-2 OS. Linking both models allows the study of drug perturbation to the cell cycle as well as in silico estimation and prediction of the relationship between the target binding and the dose, also permitting the effects of different expressions of the drug resistance protein and the ALDH enzyme. Such a coupled kinetic/dynamic model, once fully validated, has the potential for enhancing the design of optimal dosing
regimens.

Item Type:	Conference Item (Poster)
Subjects:	R Medicine > R Medicine (General) T Technology > TA Engineering (General). Civil engineering (General)
Divisions:	Faculty of Science > Engineering
Journal or Publication Title:	Scientia Pharmaceutica
Publisher:	Oesterreichische Apotheker-Verlagsgesellschaft mbH
ISSN:	0036-8709
Official Date:	2010
Dates:	Date Event 2010 UNSPECIFIED
Volume:	Vol.78
Number:	No.3
Page Range:	p. 718
Identification Number:	10.3797/scipharm.cespt.8.POT03
Status:	Not Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Conference Paper Type:	Poster
Title of Event:	8th Central European Symposium on Pharmaceutical Technology
Type of Event:	Other
Location of Event:	Graz, Austria
Date(s) of Event:	Sep 16 - 18, 2010
URI:	http://wrap.warwick.ac.uk/id/eprint/45957

Request changes or add full text files to a record

Actions (login required)

View Item